Review



fluorescent in vitro hat assay kit  (Active Motif)


Bioz Verified Symbol Active Motif is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Active Motif fluorescent in vitro hat assay kit
    <t>HAT</t> inhibitor CPTH2 decreases cell viability in tumor cells. a In <t>vitro</t> <t>HAT</t> activity was measured in nuclear extracts of Thyroid papillary K1 (gray) and clear cell renal carcinoma ccRCC 786-O (dark gray) cell lines treated with CPTH2 (100 μM) for 24 and 48 h, respectively, and compared to untreated and DMSO samples. b Cell proliferation measured in K1 (gray) and 786-O (dark gray) cell lines in DMSO or during CPTH2 treatment at increased times (h) showed strong reduction at 48 h. c FACS analysis of 786-O cell line grown in DMSO and treated for 48 h with CPTH2. d Apoptotic FACS profile and percentage of apoptotic cells strongly enhanced after 48 h CPTH2 treatment in both K1 and 786-O cell lines
    Fluorescent In Vitro Hat Assay Kit, supplied by Active Motif, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorescent+in+vitro+hat+assay+kit/pmc05885315-68-8-12?v=Active+Motif
    Average 90 stars, based on 1 article reviews
    fluorescent in vitro hat assay kit - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2"

    Article Title: KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2

    Journal: Clinical Epigenetics

    doi: 10.1186/s13148-018-0473-4

    HAT inhibitor CPTH2 decreases cell viability in tumor cells. a In vitro HAT activity was measured in nuclear extracts of Thyroid papillary K1 (gray) and clear cell renal carcinoma ccRCC 786-O (dark gray) cell lines treated with CPTH2 (100 μM) for 24 and 48 h, respectively, and compared to untreated and DMSO samples. b Cell proliferation measured in K1 (gray) and 786-O (dark gray) cell lines in DMSO or during CPTH2 treatment at increased times (h) showed strong reduction at 48 h. c FACS analysis of 786-O cell line grown in DMSO and treated for 48 h with CPTH2. d Apoptotic FACS profile and percentage of apoptotic cells strongly enhanced after 48 h CPTH2 treatment in both K1 and 786-O cell lines
    Figure Legend Snippet: HAT inhibitor CPTH2 decreases cell viability in tumor cells. a In vitro HAT activity was measured in nuclear extracts of Thyroid papillary K1 (gray) and clear cell renal carcinoma ccRCC 786-O (dark gray) cell lines treated with CPTH2 (100 μM) for 24 and 48 h, respectively, and compared to untreated and DMSO samples. b Cell proliferation measured in K1 (gray) and 786-O (dark gray) cell lines in DMSO or during CPTH2 treatment at increased times (h) showed strong reduction at 48 h. c FACS analysis of 786-O cell line grown in DMSO and treated for 48 h with CPTH2. d Apoptotic FACS profile and percentage of apoptotic cells strongly enhanced after 48 h CPTH2 treatment in both K1 and 786-O cell lines

    Techniques Used: In Vitro, Activity Assay

    CPTH2 preferentially inhibits HAT-p300 in ccRCC 786-O cells. a In vitro HAT assay was performed on recombinant p300 (red), GCN5 (green), and PCAF (blue). Control ( c ) in presence of HAT inhibitor anacardic acid, AA (15 μM), and CPTH2 (400 and 600 μM). CPTH2 shows higher selectivity in the inhibition of p300. b Prolonged incubation with CPTH2 does not affect mRNA expression of p300. c treatment of ccRCC 786-O with CPTH2 (100 μM) at indicated times clears the immunostaining of p300 with respect to untreated and DMSO cells. d Silencing of p300 in 786-O cells caused decrease of p300-mRNA expression (light gray) and lowering of cell viability (gray) with respect to nc control. e Cytoskeleton of 786-O cells silenced for p300 (18 h) was stained with phalloidine. It is heavily modified and fully comparable to the cytoskeleton of cells treated with CPTH2 shown in Fig. , and histogram with percentage of stress fibers/cell found after 24 h p300 si (light gray) compared to control, nc (dark gray). f Histograms reporting the number of proliferating cells, percentage of stress fiber/cell and number of migrating cells in, respectively, nc control (black) and p300 si cells (gray) grown in DMSO and in CPTH2 for 48 h
    Figure Legend Snippet: CPTH2 preferentially inhibits HAT-p300 in ccRCC 786-O cells. a In vitro HAT assay was performed on recombinant p300 (red), GCN5 (green), and PCAF (blue). Control ( c ) in presence of HAT inhibitor anacardic acid, AA (15 μM), and CPTH2 (400 and 600 μM). CPTH2 shows higher selectivity in the inhibition of p300. b Prolonged incubation with CPTH2 does not affect mRNA expression of p300. c treatment of ccRCC 786-O with CPTH2 (100 μM) at indicated times clears the immunostaining of p300 with respect to untreated and DMSO cells. d Silencing of p300 in 786-O cells caused decrease of p300-mRNA expression (light gray) and lowering of cell viability (gray) with respect to nc control. e Cytoskeleton of 786-O cells silenced for p300 (18 h) was stained with phalloidine. It is heavily modified and fully comparable to the cytoskeleton of cells treated with CPTH2 shown in Fig. , and histogram with percentage of stress fibers/cell found after 24 h p300 si (light gray) compared to control, nc (dark gray). f Histograms reporting the number of proliferating cells, percentage of stress fiber/cell and number of migrating cells in, respectively, nc control (black) and p300 si cells (gray) grown in DMSO and in CPTH2 for 48 h

    Techniques Used: In Vitro, HAT Assay, Recombinant, Control, Inhibition, Incubation, Expressing, Immunostaining, Staining, Modification



    Similar Products

    fluorescent in vitro hat assay kit  (Active Motif)
    90
    Active Motif fluorescent in vitro hat assay kit
    <t>HAT</t> inhibitor CPTH2 decreases cell viability in tumor cells. a In <t>vitro</t> <t>HAT</t> activity was measured in nuclear extracts of Thyroid papillary K1 (gray) and clear cell renal carcinoma ccRCC 786-O (dark gray) cell lines treated with CPTH2 (100 μM) for 24 and 48 h, respectively, and compared to untreated and DMSO samples. b Cell proliferation measured in K1 (gray) and 786-O (dark gray) cell lines in DMSO or during CPTH2 treatment at increased times (h) showed strong reduction at 48 h. c FACS analysis of 786-O cell line grown in DMSO and treated for 48 h with CPTH2. d Apoptotic FACS profile and percentage of apoptotic cells strongly enhanced after 48 h CPTH2 treatment in both K1 and 786-O cell lines
    Fluorescent In Vitro Hat Assay Kit, supplied by Active Motif, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fluorescent+in+vitro+hat+assay+kit/pmc05885315-68-8-12?v=Active+Motif
    Average 90 stars, based on 1 article reviews
    fluorescent in vitro hat assay kit - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    HAT inhibitor CPTH2 decreases cell viability in tumor cells. a In vitro HAT activity was measured in nuclear extracts of Thyroid papillary K1 (gray) and clear cell renal carcinoma ccRCC 786-O (dark gray) cell lines treated with CPTH2 (100 μM) for 24 and 48 h, respectively, and compared to untreated and DMSO samples. b Cell proliferation measured in K1 (gray) and 786-O (dark gray) cell lines in DMSO or during CPTH2 treatment at increased times (h) showed strong reduction at 48 h. c FACS analysis of 786-O cell line grown in DMSO and treated for 48 h with CPTH2. d Apoptotic FACS profile and percentage of apoptotic cells strongly enhanced after 48 h CPTH2 treatment in both K1 and 786-O cell lines

    Journal: Clinical Epigenetics

    Article Title: KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2

    doi: 10.1186/s13148-018-0473-4

    Figure Lengend Snippet: HAT inhibitor CPTH2 decreases cell viability in tumor cells. a In vitro HAT activity was measured in nuclear extracts of Thyroid papillary K1 (gray) and clear cell renal carcinoma ccRCC 786-O (dark gray) cell lines treated with CPTH2 (100 μM) for 24 and 48 h, respectively, and compared to untreated and DMSO samples. b Cell proliferation measured in K1 (gray) and 786-O (dark gray) cell lines in DMSO or during CPTH2 treatment at increased times (h) showed strong reduction at 48 h. c FACS analysis of 786-O cell line grown in DMSO and treated for 48 h with CPTH2. d Apoptotic FACS profile and percentage of apoptotic cells strongly enhanced after 48 h CPTH2 treatment in both K1 and 786-O cell lines

    Article Snippet: Histone acetyltransferase activity was measured with fluorescent in vitro HAT Assay Kit (Active Motif, CA) in nuclear extracts (7 μg) prepared with EpiQuikTM Nuclear Extraction Kit I (Epigentek, NY) treated 24 or 48 h with CPTH2 100 μM or solvent DMSO.

    Techniques: In Vitro, Activity Assay

    CPTH2 preferentially inhibits HAT-p300 in ccRCC 786-O cells. a In vitro HAT assay was performed on recombinant p300 (red), GCN5 (green), and PCAF (blue). Control ( c ) in presence of HAT inhibitor anacardic acid, AA (15 μM), and CPTH2 (400 and 600 μM). CPTH2 shows higher selectivity in the inhibition of p300. b Prolonged incubation with CPTH2 does not affect mRNA expression of p300. c treatment of ccRCC 786-O with CPTH2 (100 μM) at indicated times clears the immunostaining of p300 with respect to untreated and DMSO cells. d Silencing of p300 in 786-O cells caused decrease of p300-mRNA expression (light gray) and lowering of cell viability (gray) with respect to nc control. e Cytoskeleton of 786-O cells silenced for p300 (18 h) was stained with phalloidine. It is heavily modified and fully comparable to the cytoskeleton of cells treated with CPTH2 shown in Fig. , and histogram with percentage of stress fibers/cell found after 24 h p300 si (light gray) compared to control, nc (dark gray). f Histograms reporting the number of proliferating cells, percentage of stress fiber/cell and number of migrating cells in, respectively, nc control (black) and p300 si cells (gray) grown in DMSO and in CPTH2 for 48 h

    Journal: Clinical Epigenetics

    Article Title: KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2

    doi: 10.1186/s13148-018-0473-4

    Figure Lengend Snippet: CPTH2 preferentially inhibits HAT-p300 in ccRCC 786-O cells. a In vitro HAT assay was performed on recombinant p300 (red), GCN5 (green), and PCAF (blue). Control ( c ) in presence of HAT inhibitor anacardic acid, AA (15 μM), and CPTH2 (400 and 600 μM). CPTH2 shows higher selectivity in the inhibition of p300. b Prolonged incubation with CPTH2 does not affect mRNA expression of p300. c treatment of ccRCC 786-O with CPTH2 (100 μM) at indicated times clears the immunostaining of p300 with respect to untreated and DMSO cells. d Silencing of p300 in 786-O cells caused decrease of p300-mRNA expression (light gray) and lowering of cell viability (gray) with respect to nc control. e Cytoskeleton of 786-O cells silenced for p300 (18 h) was stained with phalloidine. It is heavily modified and fully comparable to the cytoskeleton of cells treated with CPTH2 shown in Fig. , and histogram with percentage of stress fibers/cell found after 24 h p300 si (light gray) compared to control, nc (dark gray). f Histograms reporting the number of proliferating cells, percentage of stress fiber/cell and number of migrating cells in, respectively, nc control (black) and p300 si cells (gray) grown in DMSO and in CPTH2 for 48 h

    Article Snippet: Histone acetyltransferase activity was measured with fluorescent in vitro HAT Assay Kit (Active Motif, CA) in nuclear extracts (7 μg) prepared with EpiQuikTM Nuclear Extraction Kit I (Epigentek, NY) treated 24 or 48 h with CPTH2 100 μM or solvent DMSO.

    Techniques: In Vitro, HAT Assay, Recombinant, Control, Inhibition, Incubation, Expressing, Immunostaining, Staining, Modification